Pharma Aids (DHA:PHARMAID) ROCE %: 21.92% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:PHARMAID Pharma Aids Ltd DHA:PHARMAID
73 GF Score
Price BDT644.70
GF Value BDT758.56
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Pharma Aids ROCE %?

Pharma Aids DHA:PHARMAID -2.55% 73 ROCE % is 21.92% as of Mar. 2026. GuruFocus rates DHA:PHARMAID with a GF Score™ of 73/100 and a GF Value™ of BDT758.56 (Modestly Undervalued). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Pharma Aids's annualized ROCE % for the quarter that ended in Mar. 2026 was 21.92%.

Pharma Aids  (DHA:PHARMAID) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Pharma Aids ROCE % Related Terms

Pharma Aids ROCE % Historical Data

* Premium members only.

The historical data trend for Pharma Aids's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharma Aids ROCE % Chart

Pharma Aids Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.16 17.99 3.55 27.02 21.63

Pharma Aids Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.80 18.12 25.77 25.95 21.92
DHA:PHARMAID
73GF Score
Pharma Aids Ltd DHA:PHARMAID
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharma Aids ROCE % Calculation

Pharma Aids's annualized ROCE % for the fiscal year that ended in Jun. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=84.072/( ( (480.192 - 137.298) + (580.938 - 146.39) )/ 2 )
=84.072/( (342.894+434.548)/ 2 )
=84.072/388.721
=21.63 %

Pharma Aids's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=104.968/( ( (637.713 - 168.557) + (647.208 - 158.482) )/ 2 )
=104.968/( ( 469.156 + 488.726 )/ 2 )
=104.968/478.941
=21.92 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 21.92% mean?
Pharma Aids (DHA:PHARMAID) has a ROCE % of 21.92% as of Mar. 2026.
Is Pharma Aids' ROCE % too high?
Pharma Aids' current ROCE % is 21.92%. The Medical Devices & Instruments industry median ROCE % is 2.26. Pharma Aids' value of 21.92% is 869.9% above this industry median. Overall, Pharma Aids has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharma Aids' ROCE % compare to ISRG and BDX?
Pharma Aids' ROCE % of 21.92% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.26. Pharma Aids' value of 21.92% is 869.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.26, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharma Aids's current ROCE % of 21.92% is 869.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharma Aids's current ROCE % is 21.92%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Aids stock overvalued right now?
Based on GuruFocus' analysis, Pharma Aids (DHA:PHARMAID) is currently considered Modestly Undervalued. The stock's GF Value™ is BDT758.56, compared to a current price of BDT644.70 — trading 15% below its estimated fair value. The current ROCE % is 21.92% and 869.9% above the Medical Devices & Instruments industry median of 2.26. Pharma Aids' overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Pharma Aids (DHA:PHARMAID), the current ROCE % is 21.92% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharma Aids (DHA:PHARMAID) Overvalued in 2026?

Based on GuruFocus' analysis, Pharma Aids stock appears to be undervalued. The current stock price of BDT644.70 is trading 15% below its estimated GF Value™ of BDT758.56. GuruFocus considers Pharma Aids to be Modestly Undervalued.

Key valuation signals for DHA:PHARMAID:

  • ROCE %: 21.92%
  • GF Value™: BDT758.56 vs. price of BDT644.70 (15% below fair value)
  • GF Score™: 73/100 with 3 warning signs
  • Industry Position: 869.9% above the Medical Devices & Instruments median

No single metric tells the full story. See the DHA:PHARMAID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharma Aids Business Description

Address 345 Segun Bagicha, 1st Floor, Ramna, Dhaka, BGD, 1000
Pharma Aids Ltd is a Bangladesh-based company engaged in the manufacturing of neutral glass ampoules, USP Type-I. Ampoules are used by pharmaceutical companies for filling liquid injections. The company produces different sizes of ampoules from 1ml to 25ml, in Clear and Amber color, and in Amber color, and of both Open Mouth (Form B and C) and Close Mouth (Form D, Din and Marzocchi type).
73GF Score

Get the complete analysis for DHA:PHARMAID

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT644.70
Price
BDT758.56
GF Value